2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1515

Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
Abstract Number: 1516

Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
Abstract Number: 1517

Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Number: 1518

Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Abstract Number: 1519

Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Abstract Number: 1520

DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome
Abstract Number: 1521

Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis
Abstract Number: 1522

Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Abstract Number: 1523

Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials
Abstract Number: 1524

Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1525

Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials
Abstract Number: 1526

Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Abstract Number: 1527

Tofacitinib Improves Left Ventricular Mass and Cardiac Output in Rheumatoid Arthritis Patients with Chronic Heart Failure
Abstract Number: 1528

Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 1529

Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].